Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12712135 | 0.87 | KMT2A (0.38) | PDE10AHSP90AB1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL6034037 | 0.84 | ABCB1 (0.46) | PDE10AHSP90AB1KMT2ACYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL11429110 | 0.82 | ABCB1 (0.44) | PDE10AHSP90AB1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL77128 | 0.80 | HTT (0.45) | HSP90AB1KMT2ACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL22574603 | 0.80 | KMT2A (0.38) | HSP90AB1KMT2ACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL25247269 | 0.79 | CYP1A2 (0.40) | HSP90AB1KMT2ACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL30954187 | 0.79 | CYP1A2 (0.40) | HSP90AB1KMT2ACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL31168241 | 0.79 | CYP1A2 (0.33) | HSP90AB1KMT2ACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL30954186 | 0.79 | CYP1A2 (0.40) | HSP90AB1KMT2ACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL28960187 | 0.78 | KMT2A (0.37) | HSP90AB1KMT2ACYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558310-B1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4299576-A1 | [1,2,4]-TRIAZOLO[A]PYRIMIDINE DERIVATIVES AS THERMALLY ACTIVATED DELAYED FLUORESCENCE (TADF) EMITTERS AND PROCESS OF PREPARATION THEREOF | Vilnius University (LT) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023099624-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3558310-A1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190315708-A1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2018118734-A1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-9303023-B2 | Pyrazole and imidazole derivatives useful as orexin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-04-05 | — | — | US | disclosed |
| EP-2675801-B1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-20070249031-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070179125-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| EP-1685124-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005047279-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
| EP-0976753-B1 | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6222035-B1 | AS ADENOSINE A.SUB.2A RECEPTOR ANTAGONISTS AND ARE USEFUL FOR THERAPY OR OR PROPHYLAXIS OF VARIOUS DISEASES INDUCED BY HYPERACTIVITY OF ADENOSINE A.SUB.2A RECEPTORS SUCH AS PARKINSON'S DISEASE, SENILE DEMENTIA OR DEPRESSION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0976753-A1 | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-4199583-A | 4-AMINO-6-HALO-2-METHYLTHIO-, METHOXY-, METHYLSULFINYL- OR METHYLSULFONYL-PYRIMIDINES | THE UPJOHN COMPANY (US) | 1980-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | PDE10A 1985/4885HSP90AB1 2238/4885KMT2A 3348/4885 |
| US-20070179125-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, MAP3K5, MAP3K20 | PDE10A 2061/4885HSP90AB1 2171/4885KMT2A 884/4885 |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM2, CHRM5 | PDE10A 2320/4885HSP90AB1 4526/4885KMT2A 463/4885 |
| US-20070142368-A1 | Substituted pyrazole compounds | AURKC, AURKA, AURKB | PDE10A 3588/4885HSP90AB1 861/4885KMT2A 1079/4885 |
| US-20190315708-A1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM4, CHRM2, CHRM5 | PDE10A 2320/4885HSP90AB1 4526/4885KMT2A 463/4885 |
| US-20070249031-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, PRKDC, MAP3K5 | PDE10A 2020/4885HSP90AB1 2228/4885KMT2A 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.